FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Gold Prices Slip Slightly in Asia as Silver Nears Record Highs on Dovish Fed Outlook 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 
Gold Prices Dip as Markets Absorb Dovish Fed Outlook; Silver Eases After Record High 
Wall Street Futures Dip as Broadcom Slides, Tech Weighed Down Despite Dovish Fed Signals 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Oil Prices Rebound as U.S.-Venezuela Tensions Offset Oversupply Concerns 
Korea Ginseng Corp. said that a collaborative research team that it co-supports with Konyang University has found a potential mechanism in red ginseng polysaccharides that reduces cognitive decline in Alzheimer's disease.
The mechanism that red ginseng polysaccharides are related to synaptic and mitochondrial pathways in Alzheimer's disease was identified in this year’s research.
With an analysis of the protein-protein interaction of 111 proteins significantly changed by injecting red ginseng polysaccharide in mice, the research team found that the protein interaction decreased significantly.
Bioinformatics analysis confirmed that these proteins play an important role in nerve and synaptic development and function related to Alzheimer's disease, contributing to the preservation of mitochondrial forms.
How red ginseng polysaccharides do this was not fully clarified due to a lack of research two years ago.
"This study is meaningful because it has confirmed the possibility of red ginseng polysaccharides as candidates for effective treatments of Alzheimer's disease in animal models,” said Moon Min-ho, a professor at the College of Medicine at Konyang University.
In 2021, Konyang University’s Research Institute for Dementia Science, led by Professor Moon Min-ho, and Korea Ginseng Corporation's Research Institute team, led by Lee Yong-yook, announced in the international scientific journal Free Radical Biology and Medicine that red ginseng polysaccharide inhibits amyloid beta aggregation.
Alzheimer's occurs when amyloid beta, a proposed cause of Alzheimer's, aggregates and accumulates in the brain.
